EW
Edwards Lifesciences Corp
Edwards Lifesciences Corp historical holders
total: 7
AKO Capital Edwards Lifesciences Corp transactions over time
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 5
- Reduced:
- 2
- Held since:
- 2018 Q2
- Held for:
- 8 quarters
- Latest activity:
- 2020 Q2
Nicolai Tangen has been an institutional investor in Edwards Lifesciences Corp (EW) since 2018 Q2. According to 2026 Q1 report, Nicolai Tangen doesn't hold any shares. The fund/company first acquired EW in 2018 Q2, initially purchasing 730,008 shares. Since the initial investment, AKO Capital has made 8 more transactions in this position.
When did Nicolai Tangen exit their EW position?
Nicolai Tangen no longer holds Edwards Lifesciences Corp (EW). They sold off their entire position in 2020 Q2, closing out an investment that began in 2018 Q2.
When did Nicolai Tangen first invest in EW?
Nicolai Tangen first invested in Edwards Lifesciences Corp (EW) in 2018 Q2 at the reported quarter-end price of $48.52 per share, acquiring 730,008 shares in their initial purchase.
What is Nicolai Tangen's average cost basis for EW?
Based on historical transaction data, Nicolai Tangen's estimated cost basis for Edwards Lifesciences Corp (EW) is approximately $62.09 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $62.09
- Weighted AVG sell price:
- $62.73
EW transactions history by AKO Capital
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2020 Q2
|
0.00%
|
$62.87
|
-100% (-2,260,704)
|
|||
|
2020 Q1
|
3.00%
|
$62.87
|
-9.04% (-224,565)
|
|||
|
2019 Q4
|
4.16%
|
$77.76
|
+28.74% (+554,772)
|
|||
|
2019 Q3
|
3.45%
|
$73.30
|
+12.84% (+219,735)
|
|||
|
2019 Q2
|
2.68%
|
$61.58
|
+24.41% (+335,709)
|
|||
|
2019 Q1
|
2.65%
|
$63.78
|
+64.77% (+540,510)
|
|||
|
2018 Q4
|
1.92%
|
$51.06
|
+27.72% (+181,107)
|
|||
|
2018 Q3
|
1.94%
|
$58.03
|
-10.49% (-76,572)
|
|||
|
2018 Q2
|
1.92%
|
$48.52
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.